ClinicalTrials.gg
CompletedNCT00721396Updated Mar 23, 2015Results posted

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules

A Phase 2 interventional study of rMenB+OMV NZ and combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine in Meningococcal Infections, sponsored by Novartis Vaccines. Completed at 60 sites in 6 countries. Open to participants aged 55 Days to 89 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-23.

Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,885
Allocation
Randomized
Ages
55 Days to 89 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing 4CMenB vaccine in Meningococcal Infections — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningococcal Infections.

Enrollment
3rd of 21
1,885 · median 508
Started
2008
with 1 other
Phase 2
7 of 21
1 open now
Registered
4th of 21
by date
Lead sponsor
10 of 21
Novartis Vaccines

Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, this one is the 3rd largest by enrollment, is one of 2 that started in 2008, is one of 7 in phase 2, and was the 4th registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

1 of the 21 studies testing 4CMenB vaccine in Meningococcal Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About 4CMenB vaccine

4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 55 Days to 89 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing 4CMenB vaccine in Meningococcal Infections, or all of them as a file.
02

Study summary

Primary :1.To demonstrate a sufficient immune response of rMenB+OMV NZ, when given concomitantly with routine infant vaccines to healthy infants at 2, 4 and 6 and 2, 3 and 4 months of age, as measured by percentage of subjects with serum bactericidal activity (SBA) titer ≥1:5, at 1 month after the third vaccination Secondary :To demonstrate that immunogenicity of routine infant vaccines, when given concomitantly with rMenB+OMV NZ to healthy infants at 2, 3 and 4 months of age, was non-inferior to that of routine infant vaccines given without rMenB+OMV NZ. 2. To demonstrate that the immunogenicity of rMenB+OMV NZ when given concomitantly with routine infant vaccines was non-inferior to that of rMenB+OMV NZ given without routine infant vaccines at 2, 4 and 6 months of age. 3. To assess prevalence of meningococcal B antibodies over the study period by evaluation of SBA, at baseline and at 1 month after third vaccination, in subjects- received routine infant vaccine without rMenB+OMV NZ.

03

Conditions studied

  • Meningococcal Infections

Keywords

  • Meningococcal disease,
  • Neisseria meningitidis serogroup B,
  • Prevention,
  • Vaccination,
  • Infants
04

Who can participate

Ages eligible
55 Days to 89 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy 2-month old infants (55-89 days, inclusive), who were born after full term pregnancy with an estimated gestational age ≥ 37 weeks and a birth weight ≥ 2.5 kg;
  • For whom a parent/legal guardian has given written after the nature of the study has been explained.

Exclusion criteria

Exclusion Criteria:

  • History of any meningococcal B or C vaccine administration;
  • prior vaccination with routine infant vaccines (Diphtheria, Tetanus, Pertussis, Polio, Haemophilus influenzae type b (Hib), and Pneumococcal antigens);
  • Previous ascertained or suspected disease caused by N. meningitidis;
  • History of severe allergic reaction after previous vaccinations or to any vaccine component;
  • Significant acute or chronic infection within the previous 7 days or axillary temperature major or equal to38 degrees within the previous day;
  • Antibiotics within 6 days prior to enrollment;
  • Any serious chronic or progressive disease;
  • Known or suspected impairment or alteration of the immune system;
  • Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,885 participants (actual)

Study arms

  • Experimental
    B+R246

    Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations.

    Biological: rMenB+OMV NZ · Biological: combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine · Biological: Pneumococcal vaccine

  • Experimental
    B246_R357

    Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age.

    Biological: rMenB+OMV NZ · Biological: combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine · Biological: Pneumococcal vaccine

  • Experimental
    B+R234

    Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations.

    Biological: rMenB+OMV NZ · Biological: combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine · Biological: Pneumococcal vaccine

  • Active comparator
    R234

    Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.

    Biological: combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine · Biological: Pneumococcal vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Serum Bactericidal Activity ≥1:5 After Receiving Three Doses of rMenB+OMV NZ Vaccine

    The percentage of subjects with serum bactericidal activity(hSBA)titer ≥1:5 after receiving three doses of rMenB+OMV NZ vaccine were evaluated to demonstrate sufficient immune response following rMenB+OMV NZ vaccination, when given concomitantly with routine infant vaccines to healthy infants. The serum bactericidal antibodies directed against serogroup B meningococci, are measured by human complement Serum Bactericidal Assay (hSBA). The immune response was considered sufficient for groups B+R246 and B+R234 if the lower limit of the 2-sided 95% confidence interval was ≥ 70% for all three strains.

    Time frame: One month after third Men B vaccination

  2. Safety and Tolerability of 3 Doses of rMenB - Concomitantly With Routine Infant Vaccines at 2, 4 and 6 Months of Age - Concomitantly With Routine Vaccines at 2, 3 and 4 Months of Age - Alone at 2, 4 and 6 Months of Age

    Safety and Tolerability of 3 Doses of rMenB was assessed in terms of the number of subjects who reported solicited local and systemic adverse events when administered concomitantly with routine infant vaccines at 2,4,6 months of age (B+R246) to when rMenB+OMV NZ and routine vaccines were administered separately (group B246_R357).

    Time frame: 10 months (groups 1 and 2); 8 months (groups 3 and 4)

Secondary outcomes

  1. Non-inferiority of Immune Response to rMenB+OMV NZ Vaccination When Administered Concomitantly With Routine Infant Vaccines at 2,4,6 Months of Age

    The non-inferiority of immune response to rMenB+OMV NZ vaccination when administered concomitantly with routine infant vaccines at 2,4,6 months of age(B+R246) to when rMenB+OMV NZ and routine vaccines were administered separately (group B246_R357)was assessed in terms of percentage of subjects With hSBA≥ 1:5.

    Time frame: One month after 3rd Men B vaccination

  2. Non-inferiority of Immune Response to Diphtheria and Tetanus Antigens When Routine Vaccines Are Administered Concomitantly With rMen+OMV NZ Vaccine

    Non-inferiority of immune response to routine vaccine antigens when routine vaccines were administered concomitantly with rMenB+OMV NZ vaccine \[group B+R234\] to when only routine vaccines were given \[Group R234\] were assessed in terms of percentage of subjects with antibody concentrations ≥0.1 IU/mL against Diphtheria and Tetanus antigens as measured by enzyme-linked immunosorbent assay.

    Time frame: One month after 3rd vaccination

  3. Geometric Mean Titers Against Neisseria Meningitidis Serogroup B, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.

    The hSBA antibody titers when rMenB+OMV NZ vaccine is administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately are reported in terms of vaccine-group-specific geometric mean titers.

    Time frame: One month after third Men B vaccination

  4. Geometric Mean Ratio of hSBA Titers, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.

    The geometric mean ratio(GMR) of GMTs at 1 month after 3rd rMenB+OMV NZ vaccination to prevaccination GMTs, when rMenB+OMV NZ was administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately.

    Time frame: one month after third Men B vaccination

  5. Percentage of Subjects With hSBA ≥1:8 After Receiving Three Doses of rMenB+OMV NZ Vaccine.

    The percentage of subjects with hSBA titers ≥1:8, following rMenB+OMV NZ vaccination when given concomitantly with routine infant vaccines to when rMenB+OMV NZ and routine vaccines were given separately.

    Time frame: One month after third Men B vaccination

  6. Percentage of Subjects With 4-fold Rise in hSBA Titers, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.

    The percentage of subjects with 4-fold rise in hSBA titers at 1 month after 3rd rMenB+OMV NZ vaccination from baseline, when rMenB+OMV NZ was administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately.

    Time frame: One month after third Men B vaccination

  7. Non-inferiority of Immune Response to Acellular Pertussis Antigens When Routine Vaccines Are Administered Concomitantly With rMen+OMV NZ Vaccine.

    Non-inferiority of immune response to routine vaccine antigens when routine vaccines were administered concomitantly with rMenB+OMV NZ vaccine \[group B+R234\] to when only routine vaccines were given \[Group R234\] were assessed in terms of percentage of subjects achieving seroconversion for pertussis antigens - Filamentous Hemagglutinin (FHA), Pertactin and Pertussis Toxoid (PT) at 1 month after 3rd vaccination versus baseline. Seroconversion was defined as a 4-fold increase for each pertussis antigen or in those initially seropositive, persistence of the pre-vaccination antibody concentration at least at the same antibody concentration as before vaccination, taking into account the decay of maternal antibodies.

    Time frame: 1 month after 3rd vaccination

07

Results

Posted Mar 23, 2015

Participant flow

Subjects were recruited from 4 centers in UK, 5 centers in Italy, 16 centers in Spain, 6 centers in Belgium, 25 centers in Germany and 4 centers in Czech Republic

Participant flow — Overall Study
MilestoneB+R246B246_R357B+R234R234
Started627628318312
Completed597592308302
Not completed30361010
Withdrew: Adverse event4720
Withdrew: Withdrawal by subject121537
Withdrew: Lost to follow-up7933
Withdrew: Protocol violation4310
Withdrew: Inappropriate enrollment0200
Withdrew: Administrative reason3010

Outcome measures

PrimaryPercentage of Subjects With Serum Bactericidal Activity ≥1:5 After Receiving Three Doses of rMenB+OMV NZ Vaccine

The percentage of subjects with serum bactericidal activity(hSBA)titer ≥1:5 after receiving three doses of rMenB+OMV NZ vaccine were evaluated to demonstrate sufficient immune response following rMenB+OMV NZ vaccination, when given concomitantly with routine infant vaccines to healthy infants. The serum bactericidal antibodies directed against serogroup B meningococci, are measured by human complement Serum Bactericidal Assay (hSBA). The immune response was considered sufficient for groups B+R246 and B+R234 if the lower limit of the 2-sided 95% confidence interval was ≥ 70% for all three strains.

Time frame:
One month after third Men B vaccination
Reported as:
Number · Percentages of subjects
Percentage of Subjects With Serum Bactericidal Activity ≥1:5 After Receiving Three Doses of rMenB+OMV NZ Vaccine
Percentages of subjectsB+R246B246_R357B+R234R234
Baseline (44/76-SL strain)N=587,589,300,2919 (6 to 11)7 (5 to 9)6 (4 to 10)6 (4 to 10)
Post vaccination (44/76-SL)N=550,561,283,26599 (98 to 100)99 (98 to 100)99 (97 to 100)4 (2 to 7)
Baseline (5/99 strain)N=580,577,294,2895 (4 to 8)7 (5 to 9)5 (3 to 8)6 (3 to 9)
Post vaccination (5/99 strain)N=551,554,285,24599 (98 to 100)99 (98 to 100)100 (99 to 100)5 (3 to 8)
Baseline(NZ98/254 strain)N=582,583,298,2923 (2 to 5)1 (0 to 2)2 (1 to 4)1 (0.083 to 2)
Post vaccination(NZ98/254 strain)N=555,559,284,26979 (75 to 82)87 (84 to 89)81 (76 to 85)4 (2 to 8)
PrimarySafety and Tolerability of 3 Doses of rMenB - Concomitantly With Routine Infant Vaccines at 2, 4 and 6 Months of Age - Concomitantly With Routine Vaccines at 2, 3 and 4 Months of Age - Alone at 2, 4 and 6 Months of Age

Safety and Tolerability of 3 Doses of rMenB was assessed in terms of the number of subjects who reported solicited local and systemic adverse events when administered concomitantly with routine infant vaccines at 2,4,6 months of age (B+R246) to when rMenB+OMV NZ and routine vaccines were administered separately (group B246_R357).

Time frame:
10 months (groups 1 and 2); 8 months (groups 3 and 4)
Reported as:
Number · Number of subjects
Safety and Tolerability of 3 Doses of rMenB - Concomitantly With Routine Infant Vaccines at 2, 4 and 6 Months of Age - Concomitantly With Routine Vaccines at 2, 3 and 4 Months of Age - Alone at 2, 4 and 6 Months of Age
Number of subjectsB+R246B246_R357B+R234R234
Tenderness (N=624,626,318,311)5294912650
Erythema (N=624,626,318,311)5065162570
Induration (N=624,626,318,311)4474652300
Swelling (N=624,626,318,311)2903241490
Change in Eating Habits (N=624,626,318,311)470473249159
Sleepiness (N=624,626,318,311)523525282224
Vomiting (N=624,626,318,311)1932349783
Diarrhea (N=624,626,318,311)284327138113
Irritability (N=624,626,318,311)543527289220
Unusual Crying (N=624,626,318,311)526515268186
Rash (N=624,626,318,311)841304239
Fever (≥38.0 C° %) ((N=624,627,318,311)501447243160
SecondaryNon-inferiority of Immune Response to rMenB+OMV NZ Vaccination When Administered Concomitantly With Routine Infant Vaccines at 2,4,6 Months of Age

The non-inferiority of immune response to rMenB+OMV NZ vaccination when administered concomitantly with routine infant vaccines at 2,4,6 months of age(B+R246) to when rMenB+OMV NZ and routine vaccines were administered separately (group B246_R357)was assessed in terms of percentage of subjects With hSBA≥ 1:5.

Time frame:
One month after 3rd Men B vaccination
Reported as:
Number · Percentages of subjects
Non-inferiority of Immune Response to rMenB+OMV NZ Vaccination When Administered Concomitantly With Routine Infant Vaccines at 2,4,6 Months of Age
Percentages of subjectsB+R246B246_R357
Baseline(44/76-SL strain)8 (6 to 11)7 (5 to 9)
1 month post 3rd vaccination(44/76-SL)N=525,534100 (99 to 100)100 (99 to 100)
Baseline(5/99 strain)N=511,5376 (4 to 8)7 (5 to 9)
1 month post 3rd vaccination(5/99strain)N=527,529100 (99 to 100)99 (98 to 100)
Baseline(NZ98/254 strain)N=554,5433 (2 to 5)1 (0 to 2)
1 month post 3rd vaccination(NZ98/254 )N=530,53479 (76 to 83)87 (84 to 90)
Statistical analysis
  • B+R246 vs B246_R357 · Miettinen and Nurminen method · Difference % (b+r246 minus b246 r357): 0 · 95% CI -1 to 1
  • B+R246 vs B246_R357 · Miettinen and Nurminen method · Difference %(b+r246 minus b246 r357): 0 · 95% CI -1 to 1
  • B+R246 vs B246_R357 · Miettinen and Nurminen method · Difference % (b+r246 minus b246 r357): -8 · 95% CI -12 to -4
SecondaryNon-inferiority of Immune Response to Diphtheria and Tetanus Antigens When Routine Vaccines Are Administered Concomitantly With rMen+OMV NZ Vaccine

Non-inferiority of immune response to routine vaccine antigens when routine vaccines were administered concomitantly with rMenB+OMV NZ vaccine \[group B+R234\] to when only routine vaccines were given \[Group R234\] were assessed in terms of percentage of subjects with antibody concentrations ≥0.1 IU/mL against Diphtheria and Tetanus antigens as measured by enzyme-linked immunosorbent assay.

Time frame:
One month after 3rd vaccination
Reported as:
Number · Percentages of subjects
Non-inferiority of Immune Response to Diphtheria and Tetanus Antigens When Routine Vaccines Are Administered Concomitantly With rMen+OMV NZ Vaccine
Percentages of subjectsB+R234R234
Baseline (Diphtheria)25 (20 to 30)21 (16 to 26)
1 month after 3rd vaccination(Diphtheria)N=261,232100 (99 to 100)100 (98 to 100)
Baseline (Tetanus)81 (76 to 86)86 (81 to 90)
1 month after 3rd vaccination (Tetanus)N=261,232100 (99 to 100)100 (98 to 100)
Statistical analysis
  • B+R234 vs R234 · Miettinen and Nurminen method · Difference %(b+r234 minus r234): 0 · 95% CI -1 to 2
  • B+R234 vs R234 · Miettinen and Nurminen · Difference %(b+r234 minus r234): 0 · 95% CI -1 to 2
SecondaryGeometric Mean Titers Against Neisseria Meningitidis Serogroup B, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.

The hSBA antibody titers when rMenB+OMV NZ vaccine is administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately are reported in terms of vaccine-group-specific geometric mean titers.

Time frame:
One month after third Men B vaccination
Reported as:
Geometric mean · Titers
Geometric Mean Titers Against Neisseria Meningitidis Serogroup B, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.
TitersB+R246B246_R357B+R234R234
Baseline (44/76-SL strain) N=556,548,285,2771.49 (1.4 to 1.59)1.36 (1.28 to 1.46)1.34 (1.23 to 1.46)1.28 (1.19 to 1.37)
post vaccination (44/76-SL) N=525,534,273,25386 (80 to 92)113 (105 to 121)82 (75 to 91)1.16 (1.09 to 1.24)
Baseline (5/99 strain) N=551,537,280,2751.3 (1.21 to 1.39)1.28 (1.2 to 1.37)1.19 (1.09 to 1.3)1.24 (1.15 to 1.33)
post vaccination (5/99 strain)N=527,529,275,236537 (494 to 584)699 (643 to 759)325 (292 to 362)1.25 (1.08 to 1.45)
Baseline (NZ98/254 strain)N=554,543,283,2781.13 (1.08 to 1.18)1.08 (1.04 to 1.13)1.06 (1 to 1.12)1.07 (1.03 to 1.1)
post vaccination (NZ98/254 strain)N=30,534,274,25712 (11 to 14)18 (16 to 20)11 (9.14 to 12)1.11 (1.04 to 1.19)
SecondaryGeometric Mean Ratio of hSBA Titers, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.

The geometric mean ratio(GMR) of GMTs at 1 month after 3rd rMenB+OMV NZ vaccination to prevaccination GMTs, when rMenB+OMV NZ was administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately.

Time frame:
one month after third Men B vaccination
Reported as:
Geometric mean · Ratio
Geometric Mean Ratio of hSBA Titers, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.
RatioB+R246B246_R357B+R234R234
44/76-SL strain (N=501,507,262,236)58 (52 to 64)83 (74 to 92)61 (53 to 70)0.91 (0.83 to 1)
5/99 strain (N=497,494,257,217)430 (379 to 487)553 (489 to 625)271 (231 to 318)1.03 (0.86 to 1.22)
NZ98/254 strain (N=504,503,258,238)11 (9.28 to 12)16 (14 to 19)10 (8.52 to 12)1.05 (0.97 to 1.14)
SecondaryPercentage of Subjects With hSBA ≥1:8 After Receiving Three Doses of rMenB+OMV NZ Vaccine.

The percentage of subjects with hSBA titers ≥1:8, following rMenB+OMV NZ vaccination when given concomitantly with routine infant vaccines to when rMenB+OMV NZ and routine vaccines were given separately.

Time frame:
One month after third Men B vaccination
Reported as:
Number · Percentages of subjects
Percentage of Subjects With hSBA ≥1:8 After Receiving Three Doses of rMenB+OMV NZ Vaccine.
Percentages of subjectsB+R246B246_R357B+R234R234
Baseline (44/76-SL strain)N=556,548,285,2774 (3 to 6)3 (2 to 5)4 (2 to 7)2 (1 to 5)
Post vaccination (44/76-SL)N=525,534,273,25399 (98 to 100)100 (99 to 100)99 (97 to 100)2 (0 to 4)
Baseline (5/99 strain)N=551,537,280,2754 (2 to 6)3 (2 to 5)2 (1 to 5)4 (2 to 7)
Post vaccination (5/99 strain)N=527,529,275,236100 (99 to 100)99 (98 to 100)100 (99 to 100)3 (1 to 7)
Baseline(NZ98/254 strain)N=554,543,283,2781 (1 to 3)1 (0 to 2)1 (0.086 to 3)0.1 (0.0091 to 2)
Post vaccination(NZ98/254 strain)N=530,534,274,25767 (63 to 71)79 (75 to 82)69 (63 to 74)2 (1 to 5)
SecondaryPercentage of Subjects With 4-fold Rise in hSBA Titers, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.

The percentage of subjects with 4-fold rise in hSBA titers at 1 month after 3rd rMenB+OMV NZ vaccination from baseline, when rMenB+OMV NZ was administered concomitantly with routine infant vaccines to when rMenB+OMV NZ vaccine and routine vaccines were given separately.

Time frame:
One month after third Men B vaccination
Reported as:
Number · Percentages of subjects
Percentage of Subjects With 4-fold Rise in hSBA Titers, When rMenB+OMV NZ Vaccine is Administered Concomitantly With Routine Infant Vaccines.
Percentages of subjectsB+R246B246_R357B+R234R234
44/76-SL strain (N=501,507,262,236)97 (96 to 99)99 (97 to 99)98 (96 to 99)1 (0 to 4)
5/99 strain (N=497,494,257,217)99 (98 to 100)99 (98 to 100)100 (99 to 100)3 (1 to 7)
NZ98/254 strain (N=504,503,258,238)66 (62 to 70)78 (74 to 81)69 (63 to 75)3 (1 to 5)
SecondaryNon-inferiority of Immune Response to Acellular Pertussis Antigens When Routine Vaccines Are Administered Concomitantly With rMen+OMV NZ Vaccine.

Non-inferiority of immune response to routine vaccine antigens when routine vaccines were administered concomitantly with rMenB+OMV NZ vaccine \[group B+R234\] to when only routine vaccines were given \[Group R234\] were assessed in terms of percentage of subjects achieving seroconversion for pertussis antigens - Filamentous Hemagglutinin (FHA), Pertactin and Pertussis Toxoid (PT) at 1 month after 3rd vaccination versus baseline. Seroconversion was defined as a 4-fold increase for each pertussis antigen or in those initially seropositive, persistence of the pre-vaccination antibody concentration at least at the same antibody concentration as before vaccination, taking into account the decay of maternal antibodies.

Time frame:
1 month after 3rd vaccination
Reported as:
Number · Percentages of subjects
Non-inferiority of Immune Response to Acellular Pertussis Antigens When Routine Vaccines Are Administered Concomitantly With rMen+OMV NZ Vaccine.
Percentages of subjectsB+R234R234
FHA94 (90 to 97)95 (91 to 97)
Pertactin92 (88 to 95)95 (91 to 97)
PT97 (94 to 99)98 (95 to 99)
Statistical analysis
  • B+R234 vs R234 · Miettinen and Nurminen method · Difference %(b+r234 minus r234): -1 · 95% CI -5 to 4
  • B+R234 vs R234 · Miettinen and Nurminen method · Difference %(b+r234 minus r234): -2 · 95% CI -7 to 2
  • B+R234 vs R234 · Miettinen and Nurminen method · Difference %(b+r234 minus r234): -1 · 95% CI -4 to 2

Adverse events

Collected over Solicited and unsolicited AEs were collected for 7 days after each vaccination; SAEs, Medically attended AEs and AEs leading to premature withdrawal were collected throughout the study period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
B+R246—63/625 (10.1%)620/625 (99.2%)
B246_R357—57/627 (9.1%)623/627 (99.4%)
B+R234—19/318 (6%)316/318 (99.4%)
R234—19/312 (6.1%)305/312 (97.8%)
Most frequent serious events
Showing 10 of 91
Most frequent serious events
EventB+R246B246_R357B+R234R234
GatroenteritisInfections and infestations7/6257/6272/3184/312
BronchiolitisInfections and infestations2/6253/6272/3183/312
BronchitisInfections and infestations4/6256/6272/3182/312
VomitingGastrointestinal disorders1/6251/6273/3180/312
PyrexiaGeneral disorders5/6254/6271/3181/312
Viral infectionInfections and infestations4/6251/6270/3181/312
BronchopneumoniaInfections and infestations1/6254/6270/3181/312
PyelonephritisInfections and infestations3/6250/6270/3180/312
Urinary tract infectionInfections and infestations3/6250/6270/3181/312
ConcussionInjury, poisoning and procedural complications3/6250/6271/3180/312
Most frequent other events
Showing 10 of 23
Most frequent other events
EventB+R246B246_R357B+R234R234
IrritabilityPsychiatric disorders543/625527/627289/318220/312
SomnolenceNervous system disorders523/625525/627282/318224/312
Injection Site ErythemaGeneral disorders535/625553/627271/318229/312
Injection Site PainGeneral disorders544/625536/627279/318182/312
CryingGeneral disorders526/625516/627268/318187/312
Injection Site IndurationGeneral disorders489/625519/627254/318204/312
PyrexiaGeneral disorders514/625462/627246/318176/312
Eating disorderPsychiatric disorders470/625473/627249/318159/312
Injection Site SwellingGeneral disorders328/625383/627170/318115/312
DiarrheaGastrointestinal disorders302/625338/627145/318123/312

Baseline characteristics

Age, Continuous
Age, Continuous(days)B+R246B246_R357B+R234R234Total
Mean68.7 ± 8.968.8 ± 9.468.8 ± 9.168.1 ± 9.068.7 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)B+R246B246_R357B+R234R234Total
Female292312164159927
Male335316154153958
08

Study locations

60 sites
  • Novartis Investigational Site Nr. 59
    Edegem, Antwerpen 2650, Belgium
  • Study Investigational Site Nr. 60
    Brussels, Brussels-Capital Region 1090, Belgium
  • Novartis Investigational Site Nr. 57
    Brussels, Brussels-Capital Region 1200, Belgium
  • Novartis Investigational Site Nr. 56
    Hasselt, Limburg 3500, Belgium
  • Novartis Investigational Site Nr. 55
    Antwerp, 2018, Belgium
  • Novartis Investigational Site Nr. 58
    Namur, 5000, Belgium
  • Novartis Investigational Site Nr. 95
    Červený Kostelec, Hradec Králové 549 41, Czech Republic
  • Novartis Investigational Site Nr. 96
    Jindřichův Hradec, South Bohemian 377 01, Czech Republic
  • Novartis Investigational Site Nr. 93
    Hradec Králové, 500 00, Czech Republic
  • Novartis Investigational Site Nr. 94
    Pardubice, 530 01, Czech Republic
  • Novartis Investigational Site Nr. 68
    Bad Saulgau, Baden-Württemberg 88348, Germany
  • Novartis Investigational Site Nr. 65
    Bretten, Baden-Württemberg 75015, Germany
  • Novartis Investigational Site Nr. 62
    Kehl, Baden-Württemberg 77694, Germany
  • Novartis Investigational Site Nr. 64
    Oberstenfeld, Baden-Württemberg 71720, Germany
  • Novartis Investigational Site Nr. 66
    Welzheim, Baden-Württemberg 73642, Germany
  • Novartis Investigational Site Nr. 69
    Aschaffenburg, Bavaria 63739, Germany
  • Novartis Investigational Site Nr. 71
    Bremerhaven, Bremen 27568, Germany
  • Novartis Investigational Site Nr. 73
    Baunatal, Hesse 34225, Germany
  • Novartis Investigational Site Nr. 75
    Bramsche, Lower Saxony 49565, Germany
  • Novartis Investigational Site Nr. 81
    Bochum, North Rhine-Westphalia 44866, Germany
  • Novartis Investigational Site Nr. 79
    Heiligenhaus, North Rhine-Westphalia 42579, Germany
  • Novartis Investigational Site Nr. 80
    Kleve Materborn, North Rhine-Westphalia 47533, Germany
  • Novartis Investigational Site Nr. 78
    Monchengladbach, North Rhine-Westphalia 41236, Germany
  • Novartis Investigational Site Nr. 82
    Munster, North Rhine-Westphalia 48163, Germany
  • Novartis Investigational Site Nr. 83
    Warburg, North Rhine-Westphalia 34414, Germany
  • Novartis Investigational Site Nr. 85
    Bielefeld, North-Rhine Westphalia 33617, Germany
  • Novartis Investigational Site Nr. 61
    Mainz, Rhineland-Palatinate 55131, Germany
  • Novartis Investigational Site Nr. 67
    Schweigen, Rhineland-Palatinate 76889, Germany
  • Novartis Investigational Site Nr. 86
    Wanzleben, Saxony-Anhalt 39164, Germany
  • Novartis Investigational Site Nr. 88
    Itzenhoe, Schleswig-Holstein 25524, Germany
  • Novartis Investigational Site Nr. 89
    Itzenhoe, Schleswig-Holstein 25524, Germany
  • Novartis Investigational Site Nr. 87
    Stockelsdorf, Schleswig-Holstein 23617, Germany
  • Novartis Investigational Site Nr. 90
    Erfurt, Thuringia 99086, Germany
  • Novartis Investigational Site Nr. 70
    Berlin, 13125, Germany
  • Novartis Investigational Site Nr. 72
    Hamburg, 22415, Germany
  • Novartis Investigational Site Nr. 5
    Milano, Lombardy 20122, Italy
  • Novartis Investigational Site Nr. 52
    Milano, Lombardy 20157, Italy
  • Novartis Investigational Site Nr. 6
    Novara, Piedmont 28100, Italy
  • Novartis Investigational Site Nr. 7
    Firenze, Tuscany 50139, Italy
  • Novartis Investigational Site Nr. 9
    Padova, Veneto 35100, Italy
  • Novartis Investigational Site Nr. 46
    Santiago de Compostela, A Coruña 15706, Spain
  • Novartis Investigational Site Nr. 49
    Oviedo, Asturias 33006, Spain
  • Novartis Investigational Site Nr. 11
    Almassora, Castellón 12550, Spain
  • Novartis Investigational Site Nr. 10
    Castellon de la Plana, Castellón 12006, Spain
  • Novartis Investigational Site Nr. 12
    Vall D'Uixo, Castelló 12600, Spain
  • Novartis Investigational Site Nr. 48
    Vigo Pontevedra, Pontevedra 36204, Spain
  • Novartis Investigational Site Nr. 25
    Catarroja, Valencia 46470, Spain
  • Novartis Investigational Site Nr. 21
    La Eliana, Valencia 46183, Spain
  • Novartis Investigational Site 14
    Sagunto, Valencia 46500, Spain
  • Novartis Investigational Site Nr. 17
    Valencia, 46011, Spain
  • Novartis Investigational Site Nr. 24
    Valencia, 46017, Spain
  • Novartis Investigational Site Nr. 15
    Valencia, 46021, Spain
  • Novartis Investigational Site Nr. 18
    Valencia, 46022, Spain
  • Novartis Investigational Site Nr. 19
    Valencia, 46022, Spain
  • Novartis Investigational Site Nr. 16
    Valencia, 46024, Spain
  • Novartis Investigational Site Nr. 23
    Valencia, 46200, Spain
  • Novartis Investigational Site Nr. 1
    Oxford, South East England OX3 7LE, United Kingdom
  • Novartis Investigational Site 3
    Bristol, South West England BS8 1TH, United Kingdom
  • Novartis Investigational Site Nr. 4
    Exeter, South West England EX2 5DW, United Kingdom
  • Novartis Investigational Site Nr. 2
    London, SW17 0RE, United Kingdom
09

References and documents

Publications

  • Zafack JG, Bureau A, Skowronski DM, De Serres G. Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials. BMJ Open. 2019 May 19;9(5):e026953. doi: 10.1136/bmjopen-2018-026953. PubMed 31110098 ↗
  • Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, Kieninger D, Prymula R, Dull P, Ypma E, Toneatto D, Kimura A, Pollard AJ; European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012 Feb 8;307(6):573-82. doi: 10.1001/jama.2012.85. PubMed 22318278 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2008
First posted
Jul 24, 2008
Start
Aug 2008
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results first posted
Mar 23, 2015
Last update
Mar 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00721396
Lead sponsor
Novartis Vaccines
Responsible party
Sponsor
First posted
Jul 24, 2008
Start date
Aug 2008
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
Mar 23, 2015
Last update
Mar 23, 2015

Study contacts

Novartis Vaccines
study chair · Novartis Vaccines

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 4CMenB vaccine

Start the discussion